Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0086543 (cataract)
 29,165 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The treatments proposed to date for the prevention of secondary cataract have shown limited efficacy or have not been satisfactory due to ocular toxicity. Since it has been demonstrated that heparin can inhibit the proliferative activity of smooth muscle cells and fibroblasts in vitro and in vivo, we examined the effect of heparin at concentrations ranging from 20 to 200 micrograms/ml on the proliferation of cultured bovine lens epithelial cells (BLEC) under various culture conditions: (1) serum-free medium (SFM); (2) SFM + aqueous humor 1:1; (3) SFM +1 and 10% fetal calf serum; (4) SFM +1% retinal extract; (5) SFM +50 micrograms/ml endothelial cell growth factor; (6) SFM +10 ng/ml epidermal growth factor; (7) SFM +10 ng/ml basic fibroblast growth factor. Heparin caused no cytotoxic effects in any of the experiments. With medium 2 and 3, heparin caused dose-dependent inhibition of cell proliferation at concentrations ranging from 10 to 50 micrograms/ml. Cells cultivated in medium 4-7 with the addition of 50 micrograms/ml heparin revealed increased proliferative activity when compared with the corresponding controls. The antiproliferative activity on BLEC in medium containing aqueous humor suggests that heparin is a valuable tool for the prevention of secondary cataract in vivo.
 ...
PMID:[Effect of heparin on proliferation of cultivated bovine lens epithelial cells]. 130 8

PMMA intraocular lenses have been modified by bonding a monolayer of Heparin molecules to the surface. These Heparin surface modified (HSM) IOLs were implanted in the capsular bag after extracapsular cataract extraction. Sixty-six patients were followed for 12 months in an open safety study. No unexpected reactions or severe complications occurred. Eighty-nine per cent of the patients obtained a visual acuity (VA) of 0.5 or more at the 12-month visit. When excluding cases with preoperative pathology only one case (1.5%) had less VA than 0.5. A mild postoperative iritis was seen during the first week after surgery, and in only three cases at a later visit. Cell precipitates were seen in a small number of cases. From this study and from earlier in vitro and in vivo animal studies we draw the conclusion that the Heparin surface modified IOLs are safe for implantation in human eyes.
 ...
PMID:Heparin surface modified intraocular lenses--a one-year follow-up of a safety study. 227 60

During combined cataract extraction and intraocular lens insertion in eyes undergoing removal of silicone oil, we noted that oil became adherent to the implant. This adhesion persisted post-operatively. Although patients seemed not to be symptomatic as a result of this effect, the oil interferes with the fundal examination. Since heparin-coated intraocular lenses are more hydrophilic than unmodified lenses, oil should spread less well on these lenses and therefore be less adherent. This study was conducted to test this hypothesis. Heparin-surface-modified and unmodified polymethylmethacrylate (PMMA) lenses were immersed in 1000 centistoke neat silicone oil and in an emulsion of silicone oil taken from a patient. The lenses were washed with saline solution in an attempt to remove adherent oil. The lenses were photographed for examination and qualitative comparison. It was found that both neat and emulsified silicone oil was strongly adherent to both surface-modified and unmodified lenses, and could not easily be washed off. The heparin-coated lenses showed a tendency for adherence of emulsified oil. It is concluded that heparin coating of intraocular lenses does not prevent, though may reduce, oil adherence. We recommend that care be taken to avoid contact between oil and implant during combined oil removal and cataract extraction.
 ...
PMID:The adherence of silicone oil to standard and heparin-coated PMMA intraocular lenses. 783 51

Bacterial adherence to intraocular lenses (IOLs) could be the cause of endophthalmitis following cataract surgery and lens implantation. There are previous reports that heparin bound to the surface of poly(methyl methacrylate) (PMMA) IOLs reduces cell adhesion. In this study, the in vitro adherence of Staphylococcus epidermidis, Staphylococcus aureus, and Pseudomonas aeruginosa to regular PMMA IOLs and to heparin-surface-modified (HSM) PMMA IOLs was investigated. The three bacterial strains attached in significantly lower numbers to HSM-PMMA IOLs than to PMMA IOLs (P < .01). Heparin in solution also inhibited attachment of Staphylococcus epidermidis to regular PMMA IOLs. Heparin may reduce adherence by placing a highly hydrated layer between the bacteria and the IOL surface. Therefore, the use of HSM-PMMA IOLs could diminish the incidence of endophthalmitis.
J Cataract Refract Surg 1993 Nov
PMID:Reduced bacterial adhesion to heparin-surface-modified intraocular lenses. 827 Nov 72

To determine the appropriateness of heparin-surface-modified (HSM) lenses in eyes at risk for breakdown of the blood-aqueous barrier, 36 consecutive patients with cataracts associated with chronic recurrent or past uveitis had extracapsular cataract extraction and insertion of an HSM posterior chamber one-piece intraocular lens (IOL). Examinations for implant precipitates (IPs), fibrin membranes, IOL synechias, and visual outcome were done postoperatively. Results show that despite a recurrence of overt uveitis with keratic precipitates in 13 eyes (36.1%), IPs were seen in only six eyes (16.6%) and were generally small and few in number. An acute postoperative fibrin reaction, which is related to blood-aqueous barrier breakdown, occurred in nine eyes. Implant synechias were found in three eyes. We found that HSM provided a cell-free IOL surface in the majority of eyes at high risk for blood-aqueous barrier breakdown and uveitis. Heparin surface modification does not prevent complications but tends to protect the IOL from inflammation changes that might otherwise occur.
J Cataract Refract Surg 1993 Nov
PMID:Heparin-modified lenses for eyes at risk for breakdown of the blood-aqueous barrier during cataract surgery. 827 Nov 73

Background. Heparin, used clinically as an anticoagulant, also has anti-inflammatory properties. The purpose of this systematic review was to provide a comprehensive review regarding the efficacy and safety of heparin and its derivatives as anti-inflammatory agents. Methods. We searched the following databases up to March 2012: Pub Med, Scopus, Web of Science, Ovid, Elsevier, and Google Scholar using combination of Mesh terms. Randomized Clinical Trials (RCTs) and trials with quasi-experimental design in clinical setting published in English were included. Quality assessments of RCTs were performed using Jadad score and Consolidated Standards of Reporting Trials (CONSORT) checklist. Results. A total of 280 relevant studies were reviewed and 57 studies met the inclusion criteria. Among them 48 studies were RCTs. About 65% of articles had score of 3 and higher according to Jadad score. Twelve studies had a quality score > 40% according to CONSORT items. Asthma (n = 7), inflammatory bowel disease (n = 5), cardiopulmonary bypass (n = 8), and cataract surgery (n = 6) were the most studied disease condition. Forty studies use unfractionated heparin (UFH) for intervention; the remaining studies use low molecular weight heparin (LMWH). Conclusion. Despite the conflicting results, heparin seems to be a safe and effective anti-inflammatory agent; although it is shown that heparin can decrease the level of inflammatory biomarkers and improves patient conditions, still more data from larger rigorously designed studies are needed to support use of heparin as an anti-inflammatory agent in clinical setting. However, because of the association between inflammation, atherogenesis, thrombogenesis, and cell proliferation, heparin and related compounds with pleiotropic effects may have greater therapeutic efficacy than compounds acting against a single target.
...
PMID:Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review. 2606 3

Development of an intraocular lens (IOL) as a drug delivery device has been pursued for many years and is a promising concept in modern cataract surgery. Common postoperative conditions such as posterior capsule opacification (PCO), intraocular inflammation or the rare but severe complications of cataract surgery like endophthalmitis are potential therapeutic targets for a drug-eluting IOL. There are three techniques of pharmacological IOL modification: Firstly, surface modification of the IOL ("coating"); secondly, IOL optic modification ("soaking") and lastly, loading the IOL haptics with a slow release system. The last option does not interfere with the IOL optics at all. Therefore, a broad spectrum of pharmacological agents needs to be assessed in preclinical and clinical studies to determine which agent/IOL combination is safe and efficient. For pharmacological PCO prophylaxis, erufosine-loaded IOLs are of great clinical interest. Heparin-coated IOLs might become clinically relevant for attenuation of intraocular inflammation after cataract surgery and cefuroxime-loaded IOLs for endophthalmitis prophylaxis.
...
PMID:[Intraocular Lens as a Drug Delivery Device: State of the Art and Future Perspective]. 2687 33